Literature DB >> 1420096

Etoposide treatment suppresses atherosclerotic plaque development in cholesterol-fed rabbits.

M de la Llera-Moya1, G H Rothblat, J M Glick, J M England.   

Abstract

To study the mechanisms by which monocytes/macrophages and smooth muscle cells contribute to atherosclerotic lesions, we studied atherosclerotic plaque formation in cholesterol-fed rabbits treated with etoposide, a drug that has been shown to have several effects that could interfere with the proposed interactions between these two cell types (M.W. Aarnoudes et al, Virchows Arch B 1984;47:211-216 and M. Rozencweig et al, Cancer 1977;40:334-342). Our results show that long-term etoposide treatment of New Zealand White rabbits maintained on a high-cholesterol diet decreases the extent of fatty streak formation in the aortic intima. Moreover, the plaques formed in the presence of etoposide are thinner and at least focally have less fibrous tissue and fewer smooth muscle cell-derived foam cells than do plaques in control rabbits. These effects are independent of the extent of the diet-induced hyperlipemia or an effect of etoposide on blood cell count and may be related to the inhibition of intimal cell proliferation by etoposide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1420096     DOI: 10.1161/01.atv.12.11.1363

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  8 in total

Review 1.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

2.  Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.

Authors:  Mengyang Liu; Yuanli Chen; Ling Zhang; Qixue Wang; Xingzhe Ma; Xiaoju Li; Rong Xiang; Yan Zhu; Shucun Qin; Yang Yu; Xian-cheng Jiang; Yajun Duan; Jihong Han
Journal:  J Biol Chem       Date:  2015-04-25       Impact factor: 5.157

3.  Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.

Authors:  J H Braesen; U Beisiegel; A Niendorf
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model.

Authors:  Daniela C U Cavallini; Juliana Y Suzuki; Dulcinéia S P Abdalla; Regina C Vendramini; Nadiége D Pauly-Silveira; Mariana N Roselino; Roseli A Pinto; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2011-07-29       Impact factor: 3.876

5.  Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions.

Authors:  Elaine R Tavares; Fatima R Freitas; Jayme Diament; Raul C Maranhão
Journal:  Int J Nanomedicine       Date:  2011-10-12

6.  Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study.

Authors:  Daniela C U Cavallini; Raquel Bedani; Laura Q Bomdespacho; Regina C Vendramini; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2009-01-07       Impact factor: 3.876

7.  Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study.

Authors:  Daniela C U Cavallini; Dulcinéia S P Abdalla; Regina C Vendramini; Raquel Bedani; Laura Q Bomdespacho; Nadiége D Pauly-Silveira; Graciela F de Valdez; Elizeu A Rossi
Journal:  Lipids Health Dis       Date:  2009-10-08       Impact factor: 3.876

8.  Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles.

Authors:  Afonso A Shiozaki; Tiago Senra; Aleksandra T Morikawa; Débora F Deus; Antonio T Paladino-Filho; Ibraim M F Pinto; Raul C Maranhão
Journal:  Clinics (Sao Paulo)       Date:  2016-08       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.